You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
A new paper outlines an upcoming effort to trace tumor development and trajectory in time and space using single-cell genetics and other genomic methods.
A genetic analysis based on more than 32,000 individuals living in the US traced the ancestry, historical migration, and other patterns present in populations around the country.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.
By sequencing ancient Salmonella enterica isolates, investigators retraced the history of the bug in humans transitioning to pastoral and agricultural lifestyles.
Researchers found sub-chromosomal aneuploidy, DNA damage pathway changes, and other somatic changes in breast cells from BRCA2 mutation carriers.
In PNAS this week: gene-edited mouse model of small cell lung cancer, cystic fibrosis carrier-related conditions, and more.
MIT's Search for Extraterrestrial Genomes is developing sequencing tools to use to try to detect whether there is any life on Mars, Quartz reports.
According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.